Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
He used to be a crazy pumper and now he’s a crazy dumper. He’s just weird and off his rocker.
Yes, MHRA certification was indeed a tangible step. But that’s not what you said. Job vacancies have been vaunted as a “coiled spring” for years. Those Advent postings are simply a business with many clients continuing operations.
Yeah, trust is pretty much gone at this point. Why send this out with so much weasely language? Why say a “majority” of the material has been submitted to the publisher? Why not wait to PR until everything was submitted? Why are they PR’ing the lack of any milestone?
And no, there is no milestone in this PR. It’s all mushy “mostly done” language. That’s not an update, not reassuring about purported communication improvement, and does nothing to increase our bottom-of-the-barrel view of their management team’s competence.
Hiring spree at Advent? Are you serious? That dead horse has decomposed by now. I have been hearing about how Advent hiring is the harbinger of near term success since I first bought the stock seven or eight years ago.
Puh-lease. Go hang your hat on something tangible please.
It’s abundantly clear that the publisher hasn’t gotten everything:
“most of the work has been completed on the key section of the MAA that remained to be done”
“the majority of which have been delivered to the publisher/QC team”
Listen, if they could actually stop putting more excuses every freaking PR that’d be nice.
Last PR they said, “With this timeline, the submission of the MAA to the MHRA would take place between mid and late November.”
It’s Nov. 22nd and today’s PR made clear they didn’t event submit everything to the publisher, let alone the MHRA. I’m in too deep and been in too long to leave the stock, but I’m holding my nose the whole way.
It’s filled with caveats and loopholes.
“Majority has been submitted”
“Several weeks”
“Finalizing”
It’s like a Rorschach test for what timeline you think they’ll actually adhere to.
Actually, the best squeeze is if there are a lot of shares leant out and then on the first day of the squeeze, the owners withdraw from the share lending program en masse.
Yeah, quite conveniently they still haven’t emailed shareholders on their email list about the fiasco of their latest PR. Usually we get it right away, but I can understand why they’d want to avoid coming clean with their incompetence.
They *should* have their tail between their legs right now.
Absolutely pathetic. Self-inflicted wound after self-inflicted wound.
Their silence is the worst, until they open their mouths to try to explain their incompetence.
Do they not understand that strong investor relations are founded on trust and honesty?
Topsy turvy world where a study of 1 is an attempt to refute a study of 331.
My grandma smoked a pack day and lived to be over 100. By your logic, you should take up the habit!
Good eye. Manipulation, at least of conversation and buzz, happens both ways.
But it *would be* data if had said what you wanted it say, right? Which is why you tried to use the data point in the first place, I presume?
The fact that so many blamed the pandemic for the delays afterwards only made me more bitter about that TLD fiasco. They made those timeline statements well into the pandemic.
I really hope management is making up for this with greater candor and adherence to timelines now. That level of forthrightness is WELL overdue.
New mRNA trial results for antigen-based immunotherapy.
Not sure if this Merck/Moderna trial result had been shared here, but this is interesting. Not DCVax related since it doesn't involve dendritic cells, nor tumor lysate, but it's inspiring to see these kinds of results and really strong signal!
https://www.science.org/content/article/personalized-vaccine-melanoma-may-stave-cancer-s-return
He’s referring to the fact that the crossover arm (original placebo) had better OS than the initial treatment group.
This rationale for taking on loans has been bandied about many a time, including the handful of times that LP herself loaned the company money. "It's a loan, so they're expecting near-term milestones to be hit!"
I'll believe it when I see it. To date, a loan has never been a precursor to imminent, fast-paced action.
Applauding this PR is like congratulating Google Maps for “Welcoming you to Pennsylvania” when it hasn’t given you any turn by turn directions.
Refreshing to see someone who offers a level-headed post and hasn't swung to any extreme. Thank you!
Amen. That's really the main point of frustration among cranky longs. The goalposts keep moving, the cheerleaders keep excusing, the bears keep pouncing, and it seems like there's no adult in the room trying to have a level-headed conversation.
There's such a golden opportunity for management to show some real leadership and tone-setting, and it's absolute crickets. For such a worthy product, it's a downright shame.
Yes, adults deal with. But adults also own up to it.
My objection is not that things take longer, my objection is that management thinks credibility doesn’t matter.
We may not agree, but you have no factual basis for believing that RA submissions were in progress in 2020, 2021, or the better part 2022. There is no public statement clearly attesting to that. That is the reality. I'd venture to say that your assertion RA submissions were in progress are the half-truth and entirely opinion.
My only dot connections are between TLD release and what they had committed to doing in a public PR. Those dot connections are based on a calendar, and not over-optimistic assumptions about what's happening behind the scenes.
The majority of shareholders are management.
I'm saying that the TLD timeline they telegraphed was overpromising what they could do and that, yes, it slowed them down. They promised summer 2020 TLD. The JAMA paper itself says: "Data analysis was conducted from October 2020 to September 2021." By definition, they didn't even begin looking at data until after they said they would release it publicly.
The point is they went back on their word and didn't own up to it. That's the universal litmus test for accountability.
I'm sorry, are you suggesting that TLD was an unnecessary step in NWBO's progress? Preparing and submitting RA applications are predicated on TLD.
I think that's untenable hill to die on, frankly.
“2 years of progress” is an overreach. There's no other way to slice it.
In spring of 2020, NWBO issued a press release saying that TLD would be released by end of summer 2020. Obviously, it wasn’t. No revised timeline was ever issued, and we ended up waiting those two years for them to follow through on what they published. Then, in the same breath, there are those who praise LP’s brilliance and strategy.
Listen: either LP is brilliant and intentionally duped shareholders in a PR, or she’s not that brilliant and oversold what was feasible in a certain time frame. She can’t have been both brilliant *and* honest. It would be great if someone (anyone?) offered a bit of accountability on this point.
There have been some incremental developments in the last couple years, including build out of manufacturing capacity. But when NWBO is demonstrably behind its own timeline, I think it’s a bit rich to try to couch it as progress.
I have held this stock for six years. I’ve made decent money on it, but I really wish that posters on this site would have a bit more fair-minded approach to evaluating management. Yes, they’ve taken steps in the right direction, but objectively slower than their own timetable. Forthright communication and honesty matter — on the part of the company and on the part of those who champion/belittle them.
And then there are the real patients, who don't have the luxury to not be impatient.
HL’s point doesn’t try to argue things don’t take time. Rather, it’s a criticism of how management can telegraph a PR blitz with many events in close succession, while also knowing that things take time. All the while, HL argues, they are saying LP is an expert in this niche.
They can’t all be true without some measure of deceit or over-promising. He’s simply making that point.
Some people really suffer from a vicarious spotlight effect. The whole world is not obsessed with NWBO such that a down day is necessarily a conspiracy.
NWBO v. Canaccord et al.
Copy of the actual legal filing is linked here:
https://www.scribd.com/document/611586726/Northwest-Bio-v-Canaccord-et-al-aka-The-MMs
Is he wrong about the nearly 2 year delay since data lock? No. He isn't. We are two and half months away from reaching the two-year mark of data lock. That's after the new SAP was approved, after the statisticians were hired, after the committee had to make critical choices about when to stop the trial.
They've had nearly two years to crunch numbers and publish. Nothing made up about that. There are 24-year-old masters students who write grants, conduct research, crunch numbers, write a thesis, and publish a peer reviewed article all in the course of two years. Yet somehow this company can't get its act together?
85% may be low. This board is not a good representation. The number of folks who spout off various time-specific deadlines for certain things to happen, and there has yet to be a single release from the company (PR or otherwise) that coincides with any of the timelines ever proposed. Heck, even the quarterly reports are filed late!
I wish people would just be more honest about their own support for this company. You can support NWBO without getting glitzy, starry-eyed about something. I remember a solicitation on this board for people's best guesses for TLD release date back in mid-June. Half of those dates that people guessed have passed. It's kind of ridiculous.
The bottom line is that shareholders deserve better -- from the company, and from the loudest shareholders themselves.
No, that's not what it says. The only thing with a timeline of "by the end of the year" is the post-inspection approval/certification by the U.K.-based MHRA for the commercial-scale production of DCVax. It has nothing to do with RA approval for the treatment itself.
In simpler terms:
The place to manufacture the drug = fully approved by end of the year
Approval of the drug for use by patients = still a mystery, though it's clear they haven't submitted an application yet to any RA
I'm no fan of how management handles communication, but I think it's still a reasonable take. NWBO can't really outright say that they are "ready for commercial production" because that requires a MHRA approval. I think the OP's comment, though, was stipulating that *functionally* the system can operate at the level that would support commercial production. That's not insignificant.
*Piñata* colatas? Well, I don’t blame you too much since most longs feel pretty beat up by now…
I've written Dave Innes three unaswered emails. The fact he's willing to talk to some folks for 45 minutes on the phone, but can't be bothered to answer a thoughtful email tells me their IR has communications problems.
Yikes, I'm no fan of management, but anyone citing The Epoch Times as real news is scary enough for me...
Bingo. This is spot on. Management and their defenders continually deflect, usually toward some bogeyman: a conspiracy, "forces" armed against them, large corporate powers with their thumbs on scales. There's no shortage of appealing to sympathy for the underdog here. It's a convenient way of exonerating the underdog of having done no wrong. But of course it can do wrong!
It's a familiar refrain from some people in our political system as well -- those who would rather lash out at others without looking at the role their own transgressions have played. Sounds really familiar. And the truth is that argument is just as flawed and empty. Would that the company could be as forthright and certainly more accurate than their spring 2020 declaration of TLD "within months."